Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

9.44USD
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
$9.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
159,234
52-wk High
$14.00
52-wk Low
$4.10

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 1.66
Market Cap(Mil.): $700.87
Shares Outstanding(Mil.): 74.24
Dividend: --
Yield (%): --

Financials

  INSY.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -3.49 -- --
ROI: -164.57 1.50 12.72
ROE: -174.24 0.19 14.85

Maryland charges Insys with engaging in deceptive opioid scheme

Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.

Sep 06 2018

UPDATE 2-Maryland charges Insys with engaging in deceptive opioid scheme

Sept 6 Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.

Sep 06 2018

Maryland charges Insys engaged in deceptive opioid scheme

Sept 6 Maryland on Thursday charged Insys Therapeutics Inc with having engaged in deceptive practices that resulted in a powerful opioid medication the drugmaker produced that was meant for cancer patients being prescribed to other people.

Sep 06 2018

Insys must face Aetna lawsuit alleging fraud over opioid -judge

A federal judge has rejected Insys Therapeutics Inc's bid to escape a lawsuit by Aetna Inc accusing the drugmaker of defrauding the insurer into paying claims for an opioid intended only for use by cancer patients that was prescribed for other purposes.

Aug 27 2018

Opioid maker Insys in talks to settle New York lawsuit

Insys Therapeutics Inc is engaged in talks to settle a lawsuit by New York's attorney general seeking at least $75 million over allegations it recklessly promoted a fentanyl-based cancer pain medicine for much wider uses and bribed doctors to prescribe it.

Aug 16 2018

REFILE-UPDATE 3-Insys to pay $150 mln to settle U.S. opioid kickback probe

Aug 8 Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

Aug 08 2018

Insys to pay $150 million to settle U.S. opioid kickback probe

Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

Aug 08 2018

Insys to pay $150 mln to settle DoJ probe

Aug 8 Insys Therapeutics said on Wednesday it had reached an agreement in principle with the U.S. Department of Justice to settle a civil and criminal investigation into inappropriate sales and commercial practices by some former company employees.

Aug 08 2018

FDA declines to approve Insys Therapeutic's opioid painkiller

Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns.

Jul 27 2018

UPDATE 1-FDA declines to approve Insys Therapeutic's opioid painkiller

July 27 Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns.

Jul 27 2018

Earnings vs. Estimates